Lund, Sweden

Ulf Sjobring

This inventor holds 1 USPTO granted patent. Top assignee: Actinova Limited. Active years: 1999.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ulf Sjobring. Retrieved from https://idiyas.com/inventor/ulf-sjobring

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ulf Sjobring and Protein L Innovation.

Introduction

Ulf Sjobring is an inventor associated with Lund, Sweden. His work includes a patent concerning Protein L and hybrid proteins, which are designed to bind immunoglobulins.

Latest Patents

Sjobring is credited with 1 patent: “Protein L and hybrid proteins thereof.” The invention describes Protein L sequences that bind to immunoglobulin light chains, as well as hybrid proteins capable of binding both light and heavy chains of immunoglobulin G, particularly Protein LG. It also covers DNA sequences encoding these proteins, vectors and transformed host cells, production methods, and reagent appliances for separating and identifying immunoglobulins. The patent further describes compositions, including pharmaceutical compositions, containing the proteins.

Career Highlights

The patent reflects work on protein-based tools for immunoglobulin binding and identification. Sjobring is associated with Actinova Limited.

Collaborations

His listed coworker is Lars Bjorck.

Conclusion

Ulf Sjobring’s recorded patent focuses on Protein L and related hybrid proteins, with applications in immunoglobulin research, separation, identification, and pharmaceutical compositions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…